CN111011609A - A composition for enhancing immunity of mammals - Google Patents
A composition for enhancing immunity of mammals Download PDFInfo
- Publication number
- CN111011609A CN111011609A CN201911361296.9A CN201911361296A CN111011609A CN 111011609 A CN111011609 A CN 111011609A CN 201911361296 A CN201911361296 A CN 201911361296A CN 111011609 A CN111011609 A CN 111011609A
- Authority
- CN
- China
- Prior art keywords
- glucan
- zinc
- pharmaceutical composition
- elderberry
- edible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002708 enhancing effect Effects 0.000 title claims abstract description 19
- 230000036039 immunity Effects 0.000 title claims abstract description 19
- 241000124008 Mammalia Species 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 title abstract description 27
- 241000208829 Sambucus Species 0.000 claims abstract description 38
- 235000008995 european elder Nutrition 0.000 claims abstract description 38
- 235000018735 Sambucus canadensis Nutrition 0.000 claims abstract description 35
- 235000007123 blue elder Nutrition 0.000 claims abstract description 35
- 235000007124 elderberry Nutrition 0.000 claims abstract description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
- 229920001503 Glucan Polymers 0.000 claims abstract description 16
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims abstract description 13
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 46
- 229920002498 Beta-glucan Polymers 0.000 claims description 46
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 31
- 239000000843 powder Substances 0.000 claims description 26
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 11
- 239000011701 zinc Substances 0.000 claims description 11
- 229910052725 zinc Inorganic materials 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 9
- 210000000822 natural killer cell Anatomy 0.000 claims description 9
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 6
- 235000015203 fruit juice Nutrition 0.000 claims description 6
- 238000001694 spray drying Methods 0.000 claims description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 235000005911 diet Nutrition 0.000 claims description 5
- 230000000378 dietary effect Effects 0.000 claims description 5
- 210000002175 goblet cell Anatomy 0.000 claims description 5
- 210000004698 lymphocyte Anatomy 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000003825 pressing Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 4
- 235000013305 food Nutrition 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 3
- CANRESZKMUPMAE-UHFFFAOYSA-L Zinc lactate Chemical compound [Zn+2].CC(O)C([O-])=O.CC(O)C([O-])=O CANRESZKMUPMAE-UHFFFAOYSA-L 0.000 claims description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 3
- 239000011667 zinc carbonate Substances 0.000 claims description 3
- 235000004416 zinc carbonate Nutrition 0.000 claims description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 3
- 229940043825 zinc carbonate Drugs 0.000 claims description 3
- 239000011592 zinc chloride Substances 0.000 claims description 3
- 235000005074 zinc chloride Nutrition 0.000 claims description 3
- 229960001939 zinc chloride Drugs 0.000 claims description 3
- 239000011746 zinc citrate Substances 0.000 claims description 3
- 235000006076 zinc citrate Nutrition 0.000 claims description 3
- 229940068475 zinc citrate Drugs 0.000 claims description 3
- 229940071566 zinc glycinate Drugs 0.000 claims description 3
- 239000011576 zinc lactate Substances 0.000 claims description 3
- 235000000193 zinc lactate Nutrition 0.000 claims description 3
- 229940050168 zinc lactate Drugs 0.000 claims description 3
- 239000011787 zinc oxide Substances 0.000 claims description 3
- 229960001296 zinc oxide Drugs 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- UOXSXMSTSYWNMH-UHFFFAOYSA-L zinc;2-aminoacetate Chemical compound [Zn+2].NCC([O-])=O.NCC([O-])=O UOXSXMSTSYWNMH-UHFFFAOYSA-L 0.000 claims description 3
- 235000007319 Avena orientalis Nutrition 0.000 claims description 2
- 244000075850 Avena orientalis Species 0.000 claims description 2
- 240000008397 Ganoderma lucidum Species 0.000 claims description 2
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims description 2
- 240000005979 Hordeum vulgare Species 0.000 claims description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 claims description 2
- 240000000599 Lentinula edodes Species 0.000 claims description 2
- 235000013339 cereals Nutrition 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 230000002062 proliferating effect Effects 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 235000001715 Lentinula edodes Nutrition 0.000 claims 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims 1
- 239000011670 zinc gluconate Substances 0.000 claims 1
- 235000011478 zinc gluconate Nutrition 0.000 claims 1
- 229960000306 zinc gluconate Drugs 0.000 claims 1
- 239000002775 capsule Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 6
- 230000036737 immune function Effects 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- -1 polysaccharide compound Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 240000002900 Arthrospira platensis Species 0.000 description 2
- 235000016425 Arthrospira platensis Nutrition 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 235000003142 Sambucus nigra Nutrition 0.000 description 2
- 240000006028 Sambucus nigra Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229940045731 elderberry fruit Drugs 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229940082787 spirulina Drugs 0.000 description 2
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000208828 Caprifoliaceae Species 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 244000058477 Sambucus melanocarpa Species 0.000 description 1
- 235000007052 Sambucus melanocarpa Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 235000011022 black elderberry Nutrition 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229940108605 cyclophosphamide injection Drugs 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021022 fresh fruits Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002434 immunopotentiative effect Effects 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Physiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to an edible or pharmaceutical composition comprising glucan and a product obtained by physically treating the whole, flesh or juice of elderberry. The composition can be used for enhancing immunity of mammals.
Description
Technical Field
The present invention relates to a composition, in particular a dietary or pharmaceutical composition, for enhancing the immunity of a mammal.
Background
Enhancing the immunity of the organism and playing an important role in maintaining the normal physiological functions of the organism.
β -glucan is a polysaccharide compound composed of glucose molecules, and is an important component of cell walls of yeast, fungi and some bacteria, animal experiments and studies show that yeast β -glucan can improve cellular immune function, humoral immune function and cell activity of natural killer cells (NK) in mice, and human trial study results also show that β -glucan can effectively prevent recurrent respiratory tract infection in children, β -glucan of different origins has a main chain connection mode mainly comprising β - (1, 3) -glycosidic bonds, and a branched chain connection mode has a larger difference, β -glucan of different origins from fungi and yeast has β - (1, 6) -glycosidic bond branches (and the branches of yeast β -glucan are longer), Bao X and other studies show that the length and the degree of substitution on the main chain determine important factors of conformation and biological activity of 2- (1, 3) -glucan, and the side chain length and the degree of substitution determine the conformation of glucan with (1, 6) -branch 23- (1, 3) -3-glucan structure is better than the immune structure of glucan with no (1, 6) -branch).
Sambucus L is a plant of Caprifoliaceae, more than 20 elderberry plants are listed in the American food and drug administration (GRAS) list in the world, and only two elderberry plants such as Sambucus nigra L, Black elderberry, also called as Sambucus nigra and elderberry are listed in the American food and drug administration generally accepted safety (GRAS) list.
There is still a need to improve the body immunity enhancing effect of β -glucan.
Disclosure of Invention
It is an object of the present invention to provide a composition, in particular a dietary or pharmaceutical composition, for enhancing the immunity of a mammal.
In one aspect, the invention provides a food or pharmaceutical composition comprising glucan and the product of physical (e.g. crushing, sieving, cutting, concentrating, drying, pressing, homogenizing or combinations thereof, preferably spray drying or freeze drying) treatment of whole fruit, pulp or juice of elderberry.
In one aspect, the glucan is β -glucan, preferably, β -glucan contains β - (1, 6) -glycosidic bond branches.
In one aspect, the β -glucan is derived from a fungus (e.g., yeast, shiitake mushroom, ganoderma lucidum) or a grain (e.g., oat, barley, etc.), preferably from yeast.
In one aspect, the product of the elderberry is a fruit powder, a concentrated powder (e.g., a concentrated powder of whole, pulp, or fruit juice), a pulp, a fruit juice (or fruit pulp), or a concentrated juice (or concentrated pulp), of elderberry, preferably a concentrated powder.
In one aspect, the weight ratio of the product of glucan and elderberry is from 1: 1 to 30: 1, preferably from 6: 5 to 10: 1, more preferably from 5: 2 to 10: 1.
In one aspect, the composition further comprises a source of zinc element, preferably selected from one or a combination of zinc citrate, zinc dextran, zinc lactate, zinc glycinate, zinc oxide, zinc chloride, zinc sulfate and zinc carbonate.
In one aspect, the invention provides a process for preparing said edible or pharmaceutical composition comprising mixing, preferably homogeneously mixing, said product of glucan and elderberry.
In one aspect, the present invention provides the use of said dietary or pharmaceutical composition in the preparation of a food or medicament for enhancing the immunity of a mammal, in particular for increasing the proliferative capacity of lymphocytes, for increasing the cellular activity of natural killer cells, or for increasing the number of goblet cells.
The invention improves the triple helix structure content of glucan, especially yeast β glucan, improves the function of β -glucan for enhancing the immunity of organisms, especially improves the proliferation capacity of lymphocytes, improves the cell activity of natural killer cells, or improves the number of goblet cells.
Drawings
FIG. 1 is a graph showing a normalized congo method for determining the triple helix structure β -glucan.
Detailed Description
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In case of conflict, the present document, including definitions, will control. Preferred methods and materials are described below, but methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention. The materials, methods, and examples disclosed herein are illustrative only and not intended to be limiting.
The β -glucan (e.g., yeast β -glucan), elderberry, zinc source, and the like are commercially available or obtained by one skilled in the art according to methods known in the art.
In one embodiment, the edible or pharmaceutical composition may be obtained by mixing the various ingredients and optionally adjuvants, carriers, diluents or excipients, preferably homogeneously.
In one embodiment, the whole fruit, pulp or juice of the elderberry is physically treated to provide the product. Including but not limited to crushing, sieving, cutting, concentrating, drying, pressing, homogenizing, or combinations thereof. The drying is preferably spray drying or freeze drying. Preferably, the physical treatment retains substantially all of the components of the whole, pulp or juice of elderberry except moisture, for example, about 60%, 70%, 80%, 90% or more of all components. Preferably, the physical means of treating retains substantially all of the component species of the whole, flesh or juice of the elderberry except moisture. Preferably, the physical means does not include means for obtaining specific components from the whole, pulp or juice of elderberry by extraction, filtration, osmosis, chromatography, etc. Preferably, the physical means does not result in a significant reduction, for example a reduction of 10%, 20%, 30%, 40% or more, of any component other than water in the whole, pulp or juice of elderberry.
In one embodiment, the invention provides a food or pharmaceutical composition comprising yeast β -glucan and elderberry concentrate powder.
The elderberry concentrated powder is a product which is concentrated and processed into powder by using fresh fruits (such as whole fruits, pulp or fruit juice) through processing technologies of spray drying, freeze drying and the like. For example, 2-10 fold concentration, such as 5-fold, 6-fold, 7-fold concentration, may be performed.
The elderberry concentrated powder can also be replaced by elderberry fruit powder, elderberry fruit pulp, fruit juice (or fruit pulp) and concentrated juice (or concentrated pulp).
In one embodiment, the composition comprises 60-250 parts by weight yeast β -glucan and 12-50 parts by weight elderberry concentrate powder in one embodiment, the composition comprises 60-200 parts by weight yeast β -glucan and 20-50 parts by weight elderberry concentrate powder in one embodiment, the composition comprises 100-200 parts by weight yeast β -glucan and 20-40 parts by weight elderberry concentrate powder.
In one embodiment, the composition further comprises a source of zinc element, preferably selected from one or a combination of zinc citrate, zinc dextran, zinc lactate, zinc glycinate, zinc oxide, zinc chloride, zinc sulfate and zinc carbonate. Preferably, the amount of the zinc element source is 4 to 8 parts by weight based on the zinc element.
In one embodiment, the weight ratio of the product of glucan and elderberry is from 1: 1 to 30: 1, preferably from 6: 5 to 10: 1, more preferably from 5: 2 to 10: 1.
In one embodiment, the triple helix content of glucan, particularly yeast β glucan, is increased by physically treating the whole, pulp or juice of elderberry of the present invention (e.g., crushing, sieving, cutting, concentrating, drying, pressing, homogenizing or combinations thereof, preferably spray drying or freeze drying).
In one embodiment, the whole fruit, pulp or juice of elderberry of the present invention is treated by physical means (e.g., crushing, sieving, cutting, concentrating, drying, pressing, homogenizing or a combination thereof, preferably spray drying or freeze drying) to obtain a product which enhances the body immunity enhancing effect of β -glucan, particularly the lymphocyte proliferation ability, the cell activity of natural killer cells, or the goblet cell number increasing effect.
In one embodiment, the composition may be formulated as tablets, pills, soft capsules, hard capsules, granules, powders, solutions, suspensions, syrups, injections, and any other suitable dosage form. In one embodiment, the medicament of the invention may be administered orally. In one embodiment, the medicament of the invention may be administered parenterally.
In one embodiment, the composition is formulated as an oral formulation, preferably, the oral formulation contains more than 10% of the composition of the present invention.
In one embodiment, the composition may be combined with adjuvants, carriers, diluents, or excipients and the like by methods known in the art to make suitable dosage forms. Such as starch and the like.
Examples
Example 1
TABLE 1 Main component content of capsule of a composition having an immunity enhancing effect
According to the formula shown in table 1, the main components are respectively weighed in a GMP clean workshop and sieved by a 60-mesh sieve, the sieved materials are placed in a mixer, other auxiliary materials such as starch and the like are added, the mixture is uniformly mixed and filled in a capsule shell, and 0.5 g/capsule is prepared, so that each capsule contains 60mg of yeast β -glucan and 12mg of elderberry concentrated powder.
Example 2
TABLE 2 Main component content of capsule of a composition having an immunity enhancing effect
The operation steps are the same as example 1, and each capsule contains β -glucan 250mg of yeast and 50mg of elderberry concentrated powder.
Example 3
TABLE 3 Main component content of capsule of a composition having an immunity enhancing effect
The operation steps are the same as the example 1, and 100mg of yeast β -glucan and 30mg of elderberry concentrated powder are obtained in each capsule.
Example 4
TABLE 4 Main component content of capsules of a composition having an effect of enhancing immunity
The operation steps are the same as the example 1, and each capsule contains 60mg of yeast β -glucan, 12mg of elderberry concentrated powder and 5mg of zinc element.
Example 5
TABLE 5 Main component content of capsule of a composition having an immunity enhancing effect
The operation steps are the same as the example 1, and each capsule contains 100mg of yeast β -glucan, 100mg of elderberry concentrated powder and 10mg of zinc element.
Example 6
TABLE 6 Main component content of capsules of a composition having an effect of enhancing immunity
The operation steps are the same as the example 1, and each capsule contains yeast β -glucan 300mg, elderberry concentrated powder 10mg and zinc element 5 mg.
Comparative example 1
TABLE 7A Capsule principal ingredient
The operation steps are the same as example 1, and each capsule contains 60mg of yeast β -glucan.
Comparative example 2
TABLE 8A Capsule principal component
The operation steps are the same as example 1, and each capsule contains 12mg of elderberry concentrated powder.
Comparative example 3
The sample preparation in comparative example 3 was carried out with reference to the combination described in "a composition having immunopotentiating effect and its use (grant publication No: CN 102357105B)".
TABLE 9A Capsule principal component
The operation steps are the same as the example 1, and each capsule contains 180mg of spirulina, 100mg of stachyose and 30mg of yeast β -glucan.
Test 1-Effect of the inventive formulation on increasing the triple helix Structure of Yeast β glucan
The Congo red molecule is combined with β -glucan which is a triple helix structure, characteristic red shift occurs, and the absorbance value at 523nm after red shift has a linear relation with the mass concentration of β -glucan which is a triple helix structure under a certain condition, so that the method can be used for measuring the triple helix structure in β -glucan molecules.
The preparation of the standard curve comprises weighing 83.3mg (purity is 60%) of yeast triple helix structure β -dextran standard substance, adding DMSO to dissolve, magnetically heating and stirring until the solution is completely dissolved, and diluting to 500mL with 0.2mol/L NaCl to obtain a standard substance solution with a concentration of 100 ug/mL.
TABLE 10 Congo red group concentration gradient determination system
TABLE 11 background group concentration gradient assay System
The concentration gradient measurement system of Congo red group and background group was obtained according to tables 10 and 11. The reference test method comprises measuring absorbance value of each group at 523nm by ultraviolet-visible spectrophotometry, calculating the difference value delta OD value, preparing delta OD value as ordinate and three-strand helical dextran sample mass (ug) as abscissa, and drawing standard curve to obtain regression equation y of 0.0012x-0.0039(R is 0.0012 x-0.0039)20.9964), indicating a good linear relationship between the three-stranded helical dextran sample mass between 40 and 160ug and the absorbance difference Δ OD.
FIG. 1 is a graph showing a normalized congo method for determining the triple helix structure β -glucan.
Three-helix β -glucan content determination about 10-15 capsules of example 1, comparative example 2 and comparative example 3 were each separately taken, the capsule contents were poured out, an appropriate amount (about 1 g/part) was weighed and subjected to the same procedure as described above to determine the three-helix β -glucan content in each sample, and three samples were measured in parallel for each group, and the results were averaged, the three-helix β -glucan content of each group of samples was obtained from a standard curve, as shown in Table 10 below.
TABLE 12 Congo method for determining the weight of triple helix structure in β -glucan of each group of yeasts
As can be seen from the above table, the yeast β -glucan is not present in the active form of triple helix in nature, but only about 40% of yeast β -glucan is present in the active form of triple helix (comparative example 1), and from example 1 and comparative example 1, the addition of elderberry concentrated powder is beneficial to improving the proportion of triple helix structure in yeast β -glucan, and from the data of comparative example 3, the yeast β -glucan is compounded with spirulina and stachyose, and has no influence on the triple helix structure.
Experiment 2-Effect of the formula of the invention on enhancing immunity
To verify that the formula of the invention has the function of enhancing immunity, the following animal experiments are carried out:
SPF-grade BALB/C mice are selected for 90 mice, 6-8 weeks old, half female and half male, and are provided by Guangdong province medical experimental animal center. One week after acclimation, all mice were randomly divided into 9 groups (10/group, half female and half male), and the composition and amount of the test substances given to each group of mice are shown in the following table:
table 13 test sample table
Each group of mice was dosed as described above 1 time daily for a 4 week (28 days) experimental period. On the 14 th day of administration, mice in groups other than the blank group were intraperitoneally injected with cyclophosphamide 40mg/kg for two consecutive days. On the 29 th day of the experiment, mice were sacrificed by cervical dislocation, spleens were placed in sterile culture dishes containing precooled PBS, cell suspensions were prepared within 24 hours, and experiments of transformation of splenic lymphocytes of mice induced by Concanavalin a (ConA) (MTT method) and cell activity measurement of natural killer cells (lactate dehydrogenase (LDH) method) were performed; another 5-10cm jejunum section was fixed in neutral formaldehyde, and then intestinal sections were prepared, observed and 5 intact villi were recorded to record the number of goblet cells. The experimental data are expressed as mean ± SD, statistical analysis is performed using SPSS10.0, and significance is set at p < 0.05 using one-way anova. The results are shown in the following table.
TABLE 14 immunization index parameters of groups of mice
Note: in comparison with the blank set, the results,#P＜0.05，##p is less than 0.01; p < 0.05, P < 0.01, compared to model group; in comparison with the group of comparative example 1,▲P＜0.05，▲▲P＜0.01
as shown in Table 14, cyclophosphamide injection can significantly reduce the cellular immune function, the cell activity of natural killer cells and the intestinal immune function of mice, i.e., successfully construct an immune hypofunction model.6 example groups can significantly improve the cellular immune function, the cell activity of natural killer cells and the intestinal immune function of hypoimmune mice, and the action effect is superior to that of single yeast β -glucan (comparative example 1) and superior to that of the existing composition (comparative example 3).
Claims (9)
1. An edible or pharmaceutical composition comprises glucan and the product of physical (e.g. crushing, sieving, cutting, concentrating, drying, pressing, homogenizing or combinations thereof, preferably spray drying or freeze drying) treatment of whole fruit, pulp or juice of elderberry.
2. The edible or pharmaceutical composition of claim 1, wherein the glucan is β -glucan, preferably, the β -glucan contains β - (1, 6) -glycosidic linkages branches.
3. Edible or pharmaceutical composition according to claim 2, wherein the β -glucan is derived from fungi (e.g. yeast, lentinus edodes, ganoderma lucidum) or cereals (e.g. oats, barley), preferably from yeast.
4. The edible or pharmaceutical composition of claim 1, wherein the product of the elderberry is a fruit powder, a concentrated powder (e.g., a concentrated powder of whole, pulp, or fruit juice), a pulp, a fruit juice (or fruit pulp), or a concentrated juice (or concentrated pulp) of elderberry, preferably a concentrated powder.
5. The edible or pharmaceutical composition according to claim 1, wherein the weight ratio of the product of glucan and elderberry is from 1: 1 to 30: 1, preferably from 6: 5 to 10: 1, more preferably from 5: 2 to 10: 1.
6. The edible or pharmaceutical composition of claim 1, further comprising a source of zinc element, preferably selected from one or a combination of zinc citrate, zinc gluconate, zinc lactate, zinc glycinate, zinc oxide, zinc chloride, zinc sulfate and zinc carbonate.
7. Edible or pharmaceutical composition according to any one of claims 1 to 6, which is selected from tablets, pills, soft capsules, hard capsules, granules, powders, solutions, suspensions, syrups or injections.
8. A process for preparing a dietary or pharmaceutical composition according to any one of claims 1 to 7, comprising mixing, preferably homogeneously mixing, said product of said glucan and elderberry.
9. Use of a dietary or pharmaceutical composition according to any one of claims 1 to 7, for the preparation of a food or a medicament for enhancing the immunity of a mammal, in particular for increasing the proliferative capacity of lymphocytes, for increasing the cellular activity of natural killer cells, or for increasing the number of goblet cells.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911361296.9A CN111011609A (en) | 2019-12-24 | 2019-12-24 | A composition for enhancing immunity of mammals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911361296.9A CN111011609A (en) | 2019-12-24 | 2019-12-24 | A composition for enhancing immunity of mammals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111011609A true CN111011609A (en) | 2020-04-17 |
Family
ID=70214445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911361296.9A Pending CN111011609A (en) | 2019-12-24 | 2019-12-24 | A composition for enhancing immunity of mammals |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111011609A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557449A (en) * | 2020-05-19 | 2020-08-21 | 北京美信高科科技有限责任公司 | Composition with function of improving immunity and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101353383A (en) * | 2008-09-17 | 2009-01-28 | 山东京博控股发展有限公司 | Water-soluble yeast beta-dextran and preparation thereof |
| CN102357105A (en) * | 2011-09-30 | 2012-02-22 | 云南道衍生物科技有限公司 | Combination with effect of enhancing immunity and application thereof |
| CN109662222A (en) * | 2019-02-20 | 2019-04-23 | 西安源森生物科技有限公司 | Plant beverage and preparation method thereof with cell repair and promotion cell viability |
| CN110269224A (en) * | 2019-07-19 | 2019-09-24 | 宗欣生态科技(上海)有限公司 | A kind of elder jelly and preparation method thereof |
-
2019
- 2019-12-24 CN CN201911361296.9A patent/CN111011609A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101353383A (en) * | 2008-09-17 | 2009-01-28 | 山东京博控股发展有限公司 | Water-soluble yeast beta-dextran and preparation thereof |
| CN102357105A (en) * | 2011-09-30 | 2012-02-22 | 云南道衍生物科技有限公司 | Combination with effect of enhancing immunity and application thereof |
| CN109662222A (en) * | 2019-02-20 | 2019-04-23 | 西安源森生物科技有限公司 | Plant beverage and preparation method thereof with cell repair and promotion cell viability |
| CN110269224A (en) * | 2019-07-19 | 2019-09-24 | 宗欣生态科技(上海)有限公司 | A kind of elder jelly and preparation method thereof |
Non-Patent Citations (14)
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111557449A (en) * | 2020-05-19 | 2020-08-21 | 北京美信高科科技有限责任公司 | Composition with function of improving immunity and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3141255B1 (en) | Memory improving composition, preparation method and use thereof | |
| US6783771B2 (en) | Physiologically active substance EEM-S originating in mushrooms, process for producing the same and drugs | |
| US7977379B2 (en) | Method for angiogenesis inhibition or immunostimulation | |
| JP5658479B2 (en) | Composition showing activity such as fat reduction | |
| EP3141254B1 (en) | Lactobacillus rhamnosus rht-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases | |
| CN105996009B (en) | A kind of antioxidant and anti-aging SOD nanometer selenium peptide combinations and preparation method thereof | |
| CN111528470A (en) | Preparation method of calcium roxburgh rose complex, product and application thereof | |
| KR20230152614A (en) | Composition for improving cognitive function speed | |
| US20070027069A1 (en) | Glucan-protein complex extracted from grifola (Maitake) | |
| CN111011609A (en) | A composition for enhancing immunity of mammals | |
| WO2009102008A1 (en) | Low-molecular-weight substance derived from maitake mushroom and having immunostimulating activity and anti-tumor activity | |
| KR102040809B1 (en) | Calcium complex comprising mussel shell and oligosaccharide and uses thereof | |
| JP4323128B2 (en) | Bioactive composition | |
| JP7011347B2 (en) | A composition for relieving a hangover or a composition for preventing, ameliorating or treating alcoholic liver disease containing beta-glucan as an active ingredient. | |
| JP6099360B2 (en) | Immune function enhancer by polymer fraction of Anninkou extract | |
| JP2009024027A (en) | Physiologically active composition | |
| KR20230039856A (en) | Anti-inflammatory composition comprising complex ginsenoside composition | |
| KR101898891B1 (en) | Composition for Suppressing Side effects of Apoptosis-inducing Anti-cancer Drugs Using Ginsenoside Compound K | |
| CN108619484B (en) | Biological protein extracted from liver-protecting and alcoholism-relieving silkworm chrysalis | |
| CN113072650A (en) | Preparation method of jackfruit polysaccharide | |
| KR101184355B1 (en) | Composition for enhancement of immune function and improvement of hematopoiesis which comprises antler fermented with Cordyceps militaris KCTC 11455BP as an active ingredient, and a preparation method thereof | |
| CN111732672B (en) | Okra polygalacturonic acid with uric acid reducing effect and preparation method and application thereof | |
| KR102633006B1 (en) | Fatigue-reducing compositions containing naturally derived ingredients | |
| KR102614780B1 (en) | Composition for improving hangover and hepatic function comprising ginseng berry extract, dried yeast, and milk thistle extract | |
| CN108185245A (en) | A kind of preparation method of ginseng dish's soy drink |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200417 |
|
| RJ01 | Rejection of invention patent application after publication |